Aman Michael G, Hollway Jill A, Veenstra-VanderWeele Jeremy, Handen Benjamin L, Sanders Kevin B, Chan James, Macklin Eric, Arnold L Eugene, Wong Taylor, Newsom Cassandra, Hastie Adams Rianne, Marler Sarah, Peleg Naomi, Anagnostou Evdokia A
1 Nisonger Center, Ohio State University, Columbus, Ohio.
2 Columbia University and New York Psychiatric Institute, New York, New York.
J Child Adolesc Psychopharmacol. 2018 May;28(4):266-273. doi: 10.1089/cap.2017.0072. Epub 2018 Apr 5.
Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use.
We studied the effects of metformin (Riomet) concentrate on spatial and verbal memory in 51 youth with ASD, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management. Phase 1 was a 16-week, randomized, double-blind, placebo-controlled, parallel-group comparison of metformin (500-850 mg given twice a day) versus placebo. During Phase 2, all participants took open-label metformin from week 17 through week 32. We assessed spatial and verbal memory using the Neuropsychological Assessment 2nd Edition (NEPSY-II) and a modified children's verbal learning task.
No measures differed between participants randomized to metformin versus placebo, at either 16 or 32 weeks, after adjustment for multiple comparisons. Sixteen-week change in memory for spatial location on the NEPSY-II was nominally better among participants randomized to placebo. However, patterns of treatment response across all measures revealed no systematic differences in performance, suggesting that metformin had no effect on spatial or verbal memory in these children.
Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications.
针对人类和啮齿动物的研究表明，二甲双胍这种通常用于治疗2型糖尿病的药物，可能对记忆力有有益影响。我们试图确定二甲双胍是否能改善患有自闭症谱系障碍（ASD）且因使用非典型抗精神病药物而超重的儿童的空间或言语记忆。
我们研究了二甲双胍（Riomet）浓缩液对51名年龄在6至17岁、正在服用非典型抗精神病药物且体重显著增加、并参与二甲双胍体重管理试验的ASD青少年的空间和言语记忆的影响。第一阶段是为期16周的随机、双盲、安慰剂对照、平行组比较，比较二甲双胍（每日两次，每次500 - 850毫克）与安慰剂。在第二阶段，所有参与者从第17周持续到第32周服用开放标签的二甲双胍。我们使用《神经心理学评估第二版》（NEPSY-II）和一项改良的儿童言语学习任务来评估空间和言语记忆。
在对多重比较进行调整后，随机分配到二甲双胍组与安慰剂组的参与者在16周或32周时，各项测量指标均无差异。在随机分配到安慰剂组的参与者中，NEPSY-II上空间位置记忆的16周变化在名义上更好。然而，所有测量指标的治疗反应模式显示，表现上没有系统差异，这表明二甲双胍对这些儿童的空间或言语记忆没有影响。
尽管需要进一步研究来支持这些无效结果，但总体印象是二甲双胍不会影响正在服用非典型抗精神病药物的超重ASD青少年的记忆。
